Facebook
Twitter
LinkedIn
Forward
Small Molecules, Big Breakthroughs in Ulcerative Colitis (Archived CME/CE Webcast)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
Oral small molecules, similar to Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators, have recently emerged as alternatives to anti–tumor necrosis factor α monoclonal antibodies in the treatment of patients with ulcerative colitis (UC). As the treatment armamentarium expands in UC, so too does the difficulty of selecting the most appropriate therapy to treat those with this chronic inflammatory condition. This educational activity summarizes key clinical insights and management strategies presented during a CME/CE symposium held during ACG 2021. The desired results of this activity are to increase clinicians’ comfort with new therapeutic classes in UC and to improve outcomes for patients living with this disease.
Target Audience
This educational activity is intended for gastroenterology clinicians, including physicians, physician assistants, and nurse practitioners, involved in the care of patients with ulcerative colitis.
Learning Objectives
After completing this activity, participants will be better able to:
- Review the limitations associated with first-line treatments for moderate to severe ulcerative colitis
- Differentiate oral small molecule drugs for the treatment of ulcerative colitis
- Summarize recent clinical trial data for new and emerging oral small molecule drugs for ulcerative colitis
- Identify patients who would be good candidates for treatment with approved or emerging oral small molecule drugs according to clinical trial data
Faculty
 | David T. Rubin, MD (Chair) Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology, and Nutrition University of Chicago Medicine Chicago, Illinois |
 | Maria T. Abreu, MD Director, Crohn’s & Colitis Center Professor of Medicine Professor of Microbiology and Immunology Vice Chair for Research, Department of Medicine Chair, International Organization for the Study of Inflammatory Bowel Disease University of Miami Miller School of Medicine Miami, Florida |
 | Stephen B. Hanauer, MD Clifford Joseph Barborka Professor of Medicine Medical Director, Digestive Disease Center Feinberg School of Medicine Northwestern University Chicago, Illinois |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Maria T. Abreu, MD, is a consultant for AbbVie Inc, Alimentiv, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Bristol-Myers Squibb Company, Cosmo Pharmaceuticals, Eli Lilly and Company, Gilead, Janssen Global Services, LLC, Prometheus Laboratories, and Takeda Pharmaceuticals USA, Inc; is on the speakers bureau for Alimentiv, Arena Pharmaceuticals, Janssen Global Services, LLC, Microba, Takeda Pharmaceuticals USA, Inc, and UCB SA; and is a contracted researcher for AbbVie Inc, Bristol-Myers Squibb Company, Genentech, Inc, Gilead, Janssen Global Services, LLC, Pfizer Inc, Prometheus Laboratories, and Takeda Pharmaceuticals USA, Inc.
Stephen B. Hanauer, MD, is a consultant for AbbVie Inc, Allergan, Amgen Inc, Arena Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Cosmo Pharmaceuticals, Catalys Pacific, Covance, Eli Lilly and Company, Genentech, Inc, GlaxoSmithKline, Janssen Global Services, LLC, Merck & Co., Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Progenity, Inc, Prometheus Laboratories, Receptos, Salix Pharmaceuticals, Samsung Bioepis, Seres Therapeutics, Sorriso Pharmaceuticals, Inc, Takeda Pharmaceuticals USA, Inc, UCB SA, and VHsquared Ltd; is on the speakers bureau for AbbVie, Bristol-Myers Squibb Company, Janssen Global Services, LLC, Pfizer Inc, and Takeda Pharmaceuticals USA, Inc; is a contracted researcher for AbbVie Inc, Allergan, Amgen Inc, Celgene Corporation, Eli Lilly and Company, Genentech, Inc, GlaxoSmithKline, Janssen Global Services, LLC, Novartis Pharmaceuticals Corporation, Pfizer Inc, Prometheus Laboratories, Receptos, Takeda Pharmaceuticals USA, Inc, and UCB SA; and is on the data and safety monitoring board of Arena Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, and Prometheus Laboratories.
David T. Rubin, MD, is a consultant for AbbVie Inc, Allergan, AltruBio, Arena Pharmaceuticals, Athos Therapeutics, Atlantica, Bellatrix Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Connect Biopharma, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Galen Limited, Genentech, Inc, Gilead, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Inc, Iterative Scopes, Inc, Janssen Global Services, LLC, Materia Prima, Pfizer Inc, Prometheus Laboratories, Reistone Biopharma, Syneos Health, Takeda Pharmaceuticals USA, Inc, and Techlab, Inc; and is a contracted researcher for Takeda Pharmaceuticals USA, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus and Amedco planners, managers, and writers have no relevant commercial relationships to disclose.
Satisfactory Completion
Learners must view the webcast and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
For Physicians
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For Nurses
Interprofessional Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by MedEdicus LLC and Amedco LLC. Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.5 ANCC contact hours.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Arena Pharmaceuticals, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco LLC, or Arena Pharmaceuticals, Inc.
©2022 MedEdicus LLC. 259.3